Introduction

Systemic lupus erythematosus (SLE) is a multisystem autoimmune disorder with a broad spectrum of clinical presentations that affects mostly women. No single cause for SLE has been identified (1). It is possible that the autoimmune disorder results from the combination of predisposing genetic factors and the disturbed status of stress response mechanisms, including the sympathetic nervous system and various hormones (2).

The neuroendocrine-immune system is regarded as a fundamental network supporting the health state that could play an important role in the development of autoimmune disorders. Key players of the neuroendocrine-immune pathways are steroid hormones as well as the neurohormone melatonin (3), which is considered a modulator of haematopoiesis and immune cell function. Melatonin can stimulate cytokine production, phagocytosis and natural killer cell activity; moreover, it can skew the immune response toward a helper T cell type 1 profile, whilst at the same time possibly acting as an anti-inflammatory agent (4). Therefore, melatonin concentrations have been investigated in different autoimmune, allergic and infectious diseases (5-7). Nevertheless, the complex role of the hormone on the immune system remains unclear. Considering the obscure data regarding the melatonin concentrations in SLE, we aimed to investigate the influence of the daily hormone levels on the development and clinical manifestations of lupus in women.

Material and Methods

One hundred and fifty-seven women aged between 19 and 67 years were included in the study. One hundred and eleven patients fulfilled the modified 1997 American College of Rheumatology (ACR) classification criteria for systemic lupus erythematosus (SLE) in women. All women underwent a complete general assessment. The SLE Disease Activity Index (SLEDAI) and the systemic lupus international collaborating clinics/ACR (SLICC) index were determined by one rheumatologist (9-11). SLEDAI represents the disease activity during the last 10 days prior to the assessment, while SLICC/ACR shows damages...
(non-reversible changes, not related to active inflammation) occurring since the onset of lupus, ascertained by clinical assessment and presented for at least 6 months (10, 11).

The previous and current medication with corticosteroids (intravenous methylprednisolone pulses as well as chronic peroral prednisone use), antimalarials and immunosuppressors were registered. Blood samples from the patients were collected immediately after the hospital entrance and prior to any subsequent pulse therapy. Previous pulse therapies were applied at least thirty days before the study. The cessation of chronic corticosteroid use was not possible because of ethical reasons.

Human melatonin rhythm could respond to changes in day length and, accordingly, different melatonin secretion patterns were described in long (April-September) and short photoperiods (October-March) (12, 13). Patients with SLE were recruited between August 2010 and January 2011, and were subsequently divided in two groups according to the month of blood sample collection: long photoperiod group (samples collected in August and September, n=73) and short photoperiod group (samples collected from October to January, n=38).

Forty six controls were collected from the medical staff and medical students. They were all clinically healthy women without any connective tissue diseases. All controls were recruited in the short photoperiod months (October - January).

The experimental protocol was explained to all participants and written informed consent was obtained. The study was carried out in accordance with the Declaration of Helsinki and approved by the institutional ethical committee.

**Hormone assay**

Blood samples were taken in the morning between 8 and 10 h and stored at -20°C until assayed. Daily melatonin concentrations were investigated through Melatonin Direct RIA kits (Diasource ImmunoAssay S.A., Nivelles, Belgium) with an analytical sensitivity of 2 pg/mL, intra-assay variation of 9.8% and inter-assay variation of 9.6%.

**Statistics**

All results were presented as mean±SD [median] for continuous variables or as a frequency (%) for dichotomous variables. Categorical data were analysed through χ² test or Fisher’s exact test. Differences between the two groups were established using a Mann-Whitney or = independent t-test after a Kolmogorov-Smirnov test for normality of the distribution. Accordingly, two-tailed Spearman or Pearson correlations were calculated. All results were considered significant at the 0.05 level. Statistical analysis was conducted through SPSS v. 13 for Windows (SPSS, Chicago, IL, USA).

**Results**

The main characteristics of the investigated patients are shown in Table 1. The age did not differ significantly between the two groups (41.90±12.01 [41] vs. 43.83±12.29 [44] years, p=0.365). As expected, daily levels of melatonin in SLE women were significantly lower in the long photoperiod group than in the short photoperiod group (13.59±8.06 [12.30] vs. 17.75±7.13 pg/mL [16.05], p=0.009). During the short photoperiod, daily pineal hormone levels were significantly lower in the lupus patients in comparison to the healthy controls (17.75±7.13 [16.05] vs. 21.63±6.60 pg/mL [20.10], p=0.012).

Melatonin concentrations were inversely related to the SLEDAI (r= -0.268, p=0.004), but not to the SLICC index (Figure 1). The relationships between melatonin and the activity of the disease remained significant after controlling for age, month of the sample collection and corticosteroid doses.
was not related to the development of renal impairment, cardiac or pulmonary disturbances, serositis, vasculitis or haematological disorders (p>0.05). However, neurological disorders tended to be more frequent in the group of SLE patients with the lowest melatonin levels (41.0% vs. 25.0%, p=0.089). In order to reveal the significance of the lowest melatonin levels, the presence of different organic involvement was compared between the patients with melatonin levels below the 25th percentile and other patients. The melatonin decrease was not related to the development of renal impairment, cardiac or pulmonary disturbances, serositis, vasculitis or haematological disorders (p>0.05). However, neurological disorders tended to be more frequent in the group of SLE patients with the lowest melatonin levels (41.0% vs. 25.0%, p=0.089).

Discussion

The present study showed significantly lower daily melatonin levels in women with SLE compared to healthy women. However, in MRL/MP-fas lupus-prone mice, a different pattern, uncoupled from the light/dark cycle secretion, with paradoxically high melatonin levels during the light phase has been described (14). Since nocturnal rodents and daily active humans have very different visual and circadian systems as well as quite different responses to light, the observations of mice lupus models could not be directly transferred to SLE patients (15). To the best of our knowledge, this is the first study comparing melatonin levels in healthy women and SLE patients; however, a case report of a patient with SLE and a pineal teratoma with a subsequent malignant transformation has been described (16). Therefore, further studies are needed to confirm or reject our results.

The decreased melatonin levels in women with lupus could be a consequence of the chronic autoimmune process or immunosuppressive treatment. Immune complex deposits in the pineal gland were observed in an experimental model of SLE (17). Thus, the decreased pineal secretion could be a sign of neuropathies. The higher prevalence of neurological impairment in patients with the lowest melatonin levels supported this assumption. However, a protective role of the increased melatonin concentrations on the brain could not be excluded, considering the known antioxidant features of the hormone (18).

Exogenous corticosteroids were related to both increased and decreased nocturnal melatonin levels in healthy humans (19, 20). Increased daily melatonin levels were found in female Cushing patients irrespective of the cause, which returned to normal after the hypercortisolism correction (21). Probably, the decrease of the daily melatonin levels in SLE patients was not a consequence of the chronic corticosteroid treatment. In accordance, no relationships between melatonin levels and corticosteroid doses were established.

Melatonin concentrations were not only decreased in lupus patients but they also correlated inversely with the SLEDAI index of disease activity. Several investigations either directly or indirectly supported the relationships between the hormone and the autoimmune process. The administration of melatonin in female lupus MRL/MP-fas mice reduced the levels of autoantibodies and improved the histological changes (22). Since the hormone was added to the drinking water, the exact time of melatonin application could not be specified in the latter study, but it could be of clinical importance. For instance, the daily melatonin administration did not significantly enhance the survival of lupus NZB/W mice when injections were performed between 17:00 and 19:00h but did enhance survival when given between 08:00 and 10:00h (23). These studies suggested that, at least in female mice models of spontaneous lupus, the melatonin use was beneficial.

The first and only study of melatonin in humans with lupus was conducted by Haga et al. (24). The authors examined seasonal variations in SLE activity as well as daily melatonin levels in lupus patients living in a subarctic region. The daily melatonin plasma levels in 14 patients with identical treatment regimen tended to be higher in December than in June. They did not correlate significantly with SLEDAI, arthritis, flare, C-reactive protein, anti-DNA or anti-nuclear antibodies in June and December, but correlated inversely with erythrocyte sedimentation rate (ESR) in December. The authors concluded that melatonin levels were not related to the clinical disease activity or manifestation, although the correlation with ESR may indicate some connection to SLE disease activity (24). Our study supported the latter assumption, although the two studies were difficult to compare: the Norwegian patients were recruited in the subarctic region with minimal winter sunlight, while our study was conducted in a region with a moderate climate and 80-100 average monthly hours of sunshine during the winter (25).

Circadian and circannual fluctuations of the melatonin concentrations depend on the pineal melatonin formation, while basal daytime hormone levels might be additionally controlled by other factors (26). For instance, the neuroendocrine cells of the gastrointestinal tract could significantly affect the daytime circulating concentrations of melatonin (27). A study in pineal melatonin deficient mice indicated that different immune cells and tissues were able to synthesise melatonin; thus, they could contribute to the detectable melatonin levels in these animals (28). In the present study, only daily melatonin concentrations were determined, as in other studies (24, 29). Therefore, no information about the possible disturbances in the circadian melatonin rhythm was obtained, which was considered the main limitation of the study. Another important limitation was the lack of longitudinal data allowing the follow up of the individual melatonin changes during the SLE progression. Nevertheless, our results showed significant interrelations between the daily melatonin concentrations and SLE activity. Further studies are needed to clarify the importance of the pineal and extrapineal melatonin secretion in patients with systemic lupus erythematosus as well as the interrelations between the hormone and the autoimmunity.

Ethics Committee Approval: Ethics committee approval was received for this study.
Informed Consent: Written informed consent was received from the participants of this study.

Peer-review: Externally peer-reviewed.


Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: This study was financially supported by the Medical University Sofia (Grant No: 26/2010, Grant No: 59/2011).

References


12. Wehr TA. The durations of human melatonin secretion and sleep respond to changes in daylength (photoperiod). J Clin Endocrinol Metab 1991;73:1276-80. [CrossRef]


15. Bullough JD, Rea MS, Figueiro MG. Of mice and women: light as a circadian stimulus in breast cancer research. Cancer Causes Control 2006;17:375-83. [CrossRef]


17. Peress NS, Perillo E, Fenstermacher JD. Circumventricular organs in chronic serum sickness: a model for cerebral lupus. Biol Psychiatry 1989;26:397-07. [CrossRef]


